Scarica l'app Stockscreener
18.19
2.78%
-0.52
Pre-mercato:
18.19
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
ZBIO: Obexelimab nears launch for IgG4-RD, with a robust neuro-immunology pipeline advancing - TradingView
Why is Zenas BioPharma stock rallying 9% today? By Investing.com - Investing.com Canada
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Zenas BioPharma (ZBIO) Revenue BreakdownMain Composition - Moomoo
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright reiterates Zenas Biopharma stock rating at buy By Investing.com - Investing.com Canada
Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study - Moomoo
Zenas BioPharma reports positive phase 3 trial results for obexelimab By Investing.com - Investing.com Nigeria
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medici - The Manila Times
Zenas BioPharma Reports Positive Efficacy Results from Phase 3 INDIGO Trial of Obexelimab in IgG4-Related Disease - Quiver Quantitative
Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints - TradingView
Autoimmune trial: obexelimab slashes IgG4 flare risk 56% - Stock Titan
A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness - Yahoo Finance
Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness - Sahm
Why is Zenas BioPharma (ZBIO) Surging? Decoding the Insider Confidence Signal - Kavout
Zenas BioPharma Submits BLA to FDA for Obexelimab to Treat IgG4-Related Disease - geneonline.com
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - The Manila Times
Zenas BioPharma Announces Submission of Biologics License - GlobeNewswire
54,485,518 Common Stock of Zenas BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Zenas BioPharma Stock Slips as a June Catalyst Moves Into View - Bez Kabli
What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders - Sahm
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substa - GuruFocus
Zenas BioPharma to present obexelimab trial data at EULAR congress - Investing.com UK
Zenas BioPharma to present obexelimab trial data at EULAR congress By Investing.com - Investing.com Nigeria
Why is Zenas Biopharma stock climbing today? By Investing.com - Investing.com Australia
Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target - RTTNews
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - The Manila Times
Zenas BioPharma Announces Upcoming Presentation of Results - GlobeNewswire
Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing - Moomoo
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock - Investing.com Australia
Zenas BioPharma (ZBIO) CEO adds 60,000 shares in open-market buy - Stock Titan
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment - TipRanks
Zenas BioPharma rises as CEO continues insider purchases - MSN
Assessing Zenas BioPharma (ZBIO) Valuation After Obexelimab Phase 3 Success And New IL-17 Program Progress - Sahm
Vanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma, Inc. Common Stock (NASDAQ: ZBIO) Stock Price, News & Analysis - Kalkine
ZBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $22 - Moomoo
ZBIO SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Zenas BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss - Yahoo Finance
Zenas BioPharma 4Q Loss/Shr $1.46 >ZBIO - Moomoo
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):